Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to give written consent and are willing to follow the study schedule and requirements
• People aged 18 years or older at the time of signing the consent form
• People who have been confirmed through a tissue or cell sample to have stage II–IIIB (N2) non-squamous non-small cell lung cancer (a specific type and stage of lung cancer)
• People whose lung cancer has a known KRAS gene mutation
• People whose cancer has been assessed by a medical and surgical team as suitable for a complete surgical removal aimed at curing the cancer
• People who have at least one tumour that can be measured using standard imaging criteria
• People whose health allows them to receive a platinum-based combination chemotherapy treatment
• People with a physical fitness level rated at 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activities)
• People with adequate organ function as assessed during the screening period
• People with good heart and lung function that meets the requirements for curative surgery
• People who are able to become pregnant and are willing to use effective contraception during the study and for 120 days after the last dose of the study drug tislelizumab

Who may not be able to join:

• People who have previously received any treatment for their current lung cancer, including radiation, chemotherapy, immunotherapy, targeted therapy, or anti-blood-vessel-growth therapy
• People whose cancer is considered locally advanced and cannot be surgically removed, regardless of stage or whether it has spread
• People who have received certain immune-modifying medications (such as interferon or interleukin-2) within the 4 weeks before the first study dose
• People who have used any herbal medicines intended to control cancer within 14 days before the first study dose
• People who have received live or weakened live vaccines within 4 weeks before joining, or who are expected to need such vaccines during the study or within 5 months after the last dose of tislelizumab
• People who have needed regular corticosteroid therapy above a certain dose, or other immune-suppressing medications, within 14 days before the first study dose, where the treating doctor believes this could affect the study treatment
• People with an active autoimmune disease requiring ongoing systemic treatment, where the treating doctor believes this could affect the study treatment
• People with certain lung conditions such as interstitial lung disease, non-infectious lung inflammation, pulmonary fibrosis, or acute lung disease, or uncontrolled conditions such as diabetes, where the treating doctor believes this could affect the study treatment
• People with a history of serious illness or conditions affecting major organ systems, where the treating doctor believes this could affect the study treatment
• People who have had a severe ongoing or active infection requiring antibiotic, antifungal, or antiviral treatment within 14 days before the first study dose, including tuberculosis
• People with a known history of HIV infection
• People who have previously had an organ transplant or a stem cell transplant from a donor

Important: Always verify eligibility with the trial site directly before applying.